Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	92.71	76.25	88.21	139.26	203.13	127.44
Short-Term Investments	860.15	817.46	688.72	643.86	816.89	445.49
Cash & Short-Term Investments	952.86	893.71	776.93	783.12	1,020	572.93
Cash Growth	-5.17%	15.03%	-0.79%	-23.23%	78.04%	1.43%
Accounts Receivable	5.03	4.11	2.81	2.21	-	-
Other Receivables	-	-	1.1	0.3	7.28	-
Receivables	5.03	4.11	3.91	2.51	7.28	-
Inventory	32.03	27.62	19.08	8.49	-	-
Prepaid Expenses	43.19	40.17	33.92	38.66	36.94	15.89
Other Current Assets	-	-	-	-	-	47.86
Total Current Assets	1,033	965.6	833.84	832.77	1,064	636.68
Property, Plant & Equipment	44.33	54.55	69.79	88.12	104.23	116.07
Long-Term Investments	304.34	638.32	29.44	313.87	266.38	97.61
Other Long-Term Assets	3.93	4.72	4.06	3.96	2.9	2.6
Total Assets	1,386	1,663	937.12	1,239	1,438	852.95
Accounts Payable	19.55	16.64	9.78	18.62	16.7	17.72
Accrued Expenses	37.22	46.86	43.17	30.35	31.97	30.8
Current Portion of Leases	17.99	16.78	15.01	13.66	11.16	7.41
Current Income Taxes Payable	-	0.87	-	-	-	-
Other Current Liabilities	-	-	-	-	-	38.46
Total Current Liabilities	74.76	81.16	67.96	62.63	59.83	94.39
Long-Term Leases	26.53	40.21	56.99	72	85.94	97.79
Other Long-Term Liabilities	0.09	0.88	1.16	3.28	-	261.27
Total Liabilities	101.38	122.24	126.1	137.9	145.76	453.45
Common Stock	0.07	0.07	0.07	0.07	0.07	0.07
Additional Paid-In Capital	2,538	2,494	2,437	2,386	2,334	2,243
Retained Earnings	-453.67	-148.92	-822.65	-470.56	-238.76	-1,843
Treasury Stock	-802.49	-802.49	-802.49	-802.49	-802.49	-
Comprehensive Income & Other	2.05	-1.52	-0.44	-12.54	-1.2	0.11
Shareholders' Equity	1,284	1,541	811.02	1,101	1,292	399.5
Total Liabilities & Equity	1,386	1,663	937.12	1,239	1,438	852.95
Total Debt	44.52	56.99	72	85.66	97.09	105.2
Net Cash (Debt)	1,213	1,475	734.37	1,011	1,189	565.34
Net Cash Growth	-24.20%	100.86%	-27.39%	-14.96%	110.37%	-6.42%
Net Cash Per Share	21.03	25.48	13.20	18.46	19.67	8.19
Filing Date Shares Outstanding	58.31	57.3	56.19	55.29	54.64	69.6
Total Common Shares Outstanding	58.28	57.16	55.95	55.04	54.33	69.29
Working Capital	958.35	884.44	765.88	770.14	1,004	542.28
Book Value Per Share	22.04	26.96	14.50	20.00	23.78	5.77
Tangible Book Value	1,284	1,541	811.02	1,101	1,292	399.5
Tangible Book Value Per Share	22.04	26.96	14.50	20.00	23.78	5.77
Machinery	-	29.76	29.73	35.12	33.8	35.49
Construction In Progress	-	0.9	0.61	0.66	7.37	4.11
Leasehold Improvements	-	37.52	37.28	37.28	32.73	32.57

Updated Oct 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q